Get started
Author

Giovanni De Sabbata

Observed names: G De Sabbata, G. De Sabbata, Giovanni De Sabbata
ORCID: 0000-0001-8048-1972
Observed ORCID: 0000-0001-8048-1972
OpenAlex ID: A5040797112
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
2022 · Luca Bertamini, Stefania Oliva, et al. · Journal of Clinical Oncology · 100
PDF
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study
2020 · Paola Tacchetti, Lucia Pantani, et al. · The Lancet Haematology · 57
Persistent viremia and urine shedding of tick-borne encephalitis virus in an infected immunosuppressed patient from a new epidemic cluster in North-Eastern Italy
2015 · Ilaria Caracciolo, Matteo Bassetti, et al. · Journal of Clinical Virology · 56
Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial
2020 · Francesca Gay, Pellegrino Musto, et al. · Blood · 45
Methotrexate and cyclosporin combined therapy in severe psoriatic arthritis. A pilot study.
1994 · G Mazzanti, L Coloni, et al. · PubMed · 37
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)
2015 · Carolina Terragna, Daniel Remondini, et al. · Oncotarget · 31
PDF
Carfilzomib-based induction/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: Efficacy in high-risk patients.
2021 · Francesca Gay, Roberto Mina, et al. · Journal of Clinical Oncology · 26
A Phase III Study of Enoxaparin Versus Low-Dose Warfarin Versus Aspirin as Thromboprophylaxis for Patients with Newly Diagnosed Multiple Myeloma Treated up-Front with Thalidomide-Containing Regimens
2008 · Michele Cavo, Antonio Palumbo, et al. · Blood · 22
A Phase III Study of Enoxaparin vs Aspirin vs Low-Dose Warfarin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Thalidomide Based-Regimens.
2009 · Antonio Palumbo, Michele Cavo, et al. · Blood · 21
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials
2018 · Mattia D’Agostino, Lorenzo De Paoli, et al. · Critical Reviews in Oncology/Hematology · 17
PDF
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells
2024 · Mattia D’Agostino, Delia Rota-Scalabrini, et al. · Blood Cancer Journal · 14
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial
2021 · Roberto Mina, Antonietta Pia Falcone, et al. · Blood Cancer Journal · 14
PDF
Bortezomib, Melphalan, Prednisone and Thalidomide (Vmpt)versus Bortezomib, Melphalan and Prednisone (Vmp) Inelderly Newly Diagnosed Myeloma Patients: A Prospective,randomized, Phase Iii Study
2009 · Antonio Palumbo, Sara Bringhen, et al. · Institutional Research Information System University of Turin (University of Turin) · 7
Superior PFS2 with VTD Vs TD for Newly Diagnosed, Transplant Eligible, Multiple Myeloma (MM) Patients: Updated Analysis of Gimema MMY-3006 Study
2014 · Paola Tacchetti, Lucia Pantani, et al. · Blood · 6
A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group
2023 · Gregorio Barilà, Francesca Maria Quaglia, et al. · Annals of Hematology · 5
PDF
Efficacy and Safety of Ixazomib Induction and Maintenance in Newly Diagnosed Multiple Myeloma Patients According to the IMWG Frailty Score: A Post-Hoc Analysis of the EMN10-Unito Trial
2020 · Roberto Mina, Alessandra Larocca, et al. · Blood · 5
A real‐world retrospective–prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience
2024 · Anna Furlan, Michele Cea, et al. · Cancer Medicine · 4
PDF
Teclistamab salvage therapy for multiple myeloma relapse after allogeneic hemopoietic stem cell transplant: A case report
2023 · Francesco Zaja, Elisa Lucchini, et al. · American Journal of Hematology · 4
PDF
OAB-011: Predictors of unsustained negativity in minimal residual disease (MRD)-negative transplant-eligible newly diagnosed multiple myeloma (MM) patients enrolled in the FORTE trial
2022 · Mattia D’Agostino, Stefania Oliva, et al. · Clinical Lymphoma Myeloma & Leukemia · 4
A Prospective Randomized Trial of Bortezomib-melphalanprednisone-thalidomide Followed by Continuous Bortezomib-thalidomide for Initial Therapy of Multiple Myeloma:effect of Age and Co-morbidities
2010 · Antonio Palumbo, Sara Bringhen, et al. · Institutional Research Information System University of Turin (University of Turin) · 2
Impact of sustained MRD negativity for up to 5 years on long-term outcome of transplant-eligible newly diagnosed multiple myeloma patients enrolled in the randomized phase 2 FORTE trial.
2026 · Mattia D'Agostino, Giuseppe Bertuglia, et al. · Journal of Clinical Oncology · 1
Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study
2019 · Alessandra Larocca, Paolo Corradini, et al. · Blood · 1
P49 a Real-world Retrospective-prospective Analysis of Efficacy and Safety of Combined Ixazomib, Lenalidomide and Dexamethasone in Relapsed/refractory Multiple Myeloma: the Northern Italy Experience
2023 · A. Furlan, M. Cea, et al. · HemaSphere
Sindromi mielodisplastiche. Attualità e prospettive terapeutiche
2004 · Giorgio Paladini, Paolo Pecorari, et al. · Recenti Progressi in Medicina
Works count: 25
Citation count: 477
H-index: 12
I10-index: 12
Year
Topic
Type